Targeting TGF-beta signaling to treat osteosarcoma
c-Myc regulation by TGF-beta signaling as a therapeutic target in Osteosarcoma
This study is looking at how a new drug called TEW-7197 can help treat osteosarcoma, a type of bone cancer that can spread to the lungs, by blocking a specific signaling pathway, and it aims to find out if this can improve the way the cancer grows and how the immune system responds.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10991388 on NIH RePORTER |
What this research studies
This research investigates the role of TGF-beta signaling in osteosarcoma, a type of bone cancer that often spreads to the lungs. The study aims to evaluate the effects of a new drug, TEW-7197, which inhibits TGF-beta signaling, on the growth of osteosarcoma cells both in laboratory settings and in animal models. By understanding how this drug can alter the tumor environment and immune responses, the research seeks to improve treatment outcomes for patients with pulmonary metastatic osteosarcoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and young adults diagnosed with osteosarcoma, particularly those with pulmonary metastases.
Not a fit: Patients with non-cancerous bone conditions or those whose osteosarcoma is not metastatic may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with advanced osteosarcoma, potentially improving survival rates.
How similar studies have performed: Previous research has shown promise in targeting TGF-beta signaling in other cancers, indicating potential for success in this novel approach for osteosarcoma.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Choi, Sung Hee — Case Western Reserve University
- Study coordinator: Choi, Sung Hee
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.